फॉरेक्स के समाचार

Dollar Loses Ground Against Major Rivals Despite Powell's Hawkish Comments

The U.S. dollar shed ground against its major counterparts on Wednesday despite Federal Reserve Chair Jerome Powell, who testified before the House Financial Services Committee today, reiterating that the central bank will likely continue raising rates to contain inflation.
RTTNews | 782 दिनों पहले
Swiss Market Fails To Hold Early Gains, Ends Modestly Lower

Swiss Market Fails To Hold Early Gains, Ends Modestly Lower

After a weak start and a subsequent recovery that resulted in a positive spell till about an hour past noon on Wednesday, the Switzerland market fell into negative territory and eventually ended the day's session modestly lower.
RTTNews | 782 दिनों पहले
Aldeyra Therapeutics Gets CRL From FDA For NDA Of ADX-2191 To Treat Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics Gets CRL From FDA For NDA Of ADX-2191 To Treat Primary Vitreoretinal Lymphoma

Biotechnology company Aldeyra Therapeutics, Inc. (ALDX) announced Wednesday the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL).
RTTNews | 782 दिनों पहले
more news
Bay Street Likely To See Subdued Start

Bay Street Likely To See Subdued Start

Canadian shares are likely to open on a somewhat subdued note on Wednesday, amid a lack of positive triggers.
RTTNews | 782 दिनों पहले
Pound Drops On Rate Hike Worries After Strong Inflation Data

Pound Drops On Rate Hike Worries After Strong Inflation Data

The pound fell against its major rivals in the European session on Wednesday, as the nation's inflation came in well above consensus expectations in May, raising concerns about a bigger rate hike from the Bank of England at the monetary policy decision on Thursday.
RTTNews | 782 दिनों पहले
Bluebird Bio Says FDA Accepts BLA For Lovotibeglogene Autotemcel For Priority Review

Bluebird Bio Says FDA Accepts BLA For Lovotibeglogene Autotemcel For Priority Review

bluebird bio, Inc. (BLUE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023.
RTTNews | 782 दिनों पहले

Stay up to date!

Add न्यूज to your browser

Extension Picture